Hongming Pan

机构：Sir Run Run Shaw Hospital, Zhejiang University · ORCID：0000-0001-9199-5557

发表论文 47 篇 · 总被引 596 次 · h-index 14

代表论文

• Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial (2025 · The Lancet · 被引 128)
• China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition) (2025 · Liver Cancer · 被引 41)
• A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma (2024 · European Journal of Cancer · 被引 30)
• Genetic predisposition of six well‐defined polymorphisms in HMGB 1/ RAGE pathway to breast cancer in a large Han Chinese population (2016 · Journal of Cellular and Molecular Medicine · 被引 28)
• shRNA-interfering LSD1 inhibits proliferation and invasion of gastric cancer cells via VEGF-C/PI3K/AKT signaling pathway (2019 · World Journal of Gastrointestinal Oncology · 被引 25)
• Identification of PFKFB3 as a key factor in the development of colorectal cancer and immunotherapy resistance (2024 · Clinical and Experimental Medicine · 被引 14)